Monash IVF Group Ltd ( (AU:MVF) ) has provided an update.
Monash IVF Group reported an 11.6% increase in revenue to $140.3 million and a 10.7% rise in underlying EBITDA to $35.6 million for the first half of 2025. The company achieved a 5.5% growth in underlying NPAT to $15.8 million, aligning with its guidance. Despite industry volatility, Monash IVF maintained a 25% EBITDA margin and expanded its market share in domestic stimulated cycles by 0.6% to 21.5%. The company also experienced significant growth in its international operations, with a 74% increase in underlying EBIT. Strategic investments in infrastructure and recruitment, alongside the completion of new clinics, have bolstered Monash IVF’s market position and operational capabilities.
More about Monash IVF Group Ltd
Monash IVF Group Limited is a leader in reproductive and fertility services, including genetics, primarily operating in Australia with a growing presence in South-East Asia. The company focuses on providing assisted reproductive services, women’s imaging, and international fertility solutions.
YTD Price Performance: -6.30%
Average Trading Volume: 489,335
Technical Sentiment Consensus Rating: Hold
Current Market Cap: A$463.7M
For a thorough assessment of MVF stock, go to TipRanks’ Stock Analysis page.